These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 9779709)

  • 1. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
    Masuda N; Matsui K; Negoro S; Takifuji N; Takeda K; Yana T; Kobayashi M; Hirashima T; Kusunoki Y; Ushijima S; Kawase I; Tada T; Sawaguchi H; Fukuoka M
    J Clin Oncol; 1998 Oct; 16(10):3329-34. PubMed ID: 9779709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
    Masuda N; Fukuoka M; Kusunoki Y; Matsui K; Takifuji N; Kudoh S; Negoro S; Nishioka M; Nakagawa K; Takada M
    J Clin Oncol; 1992 Aug; 10(8):1225-9. PubMed ID: 1321891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
    Oshita F; Noda K; Nishiwaki Y; Fujita A; Kurita Y; Nakabayashi T; Tobise K; Abe S; Suzuki S; Hayashi I; Kawakami Y; Matsuda T; Tsuchiya S; Takahashi S; Tamura T; Saijo N
    J Clin Oncol; 1997 Jan; 15(1):304-9. PubMed ID: 8996157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer.
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Oncology; 2000 Aug; 59(2):105-9. PubMed ID: 10971167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
    Choi HJ; Cho BC; Shin SJ; Cheon SH; Jung JY; Chang J; Kim SK; Sohn JH; Kim JH
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):309-13. PubMed ID: 17576560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
    J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
    Asakuma M; Yamamoto M; Wada M; Ryuge S; Katono K; Yokoba M; Fukui T; Takakura A; Otani S; Maki S; Igawa S; Yanaihara T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1529-36. PubMed ID: 22415148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination of irinotecan hydrochloride and etoposide for treatment of refractory or relapsed small-cell lung cancer].
    Negoro S; Masuda N
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1105-8. PubMed ID: 10945003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
    Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
    J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer.
    Ando M; Kobayashi K; Yoshimura A; Kurimoto F; Seike M; Nara M; Moriyama G; Mizutani H; Hibino S; Gemma A; Okano T; Shibuya M; Kudoh S
    Lung Cancer; 2004 Apr; 44(1):121-7. PubMed ID: 15013590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.
    Naka N; Kawahara M; Okishio K; Hosoe S; Ogawara M; Atagi S; Takemoto Y; Ueno K; Kawaguchi T; Tsuchiyama T; Furuse K
    Lung Cancer; 2002 Sep; 37(3):319-23. PubMed ID: 12234702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer.
    Kubota K; Nishiwaki Y; Kakinuma R; Hojo F; Matsumoto T; Ohmatsu H; Sekine I; Yokozaki M; Goto K; Ebi N; Kodama T
    J Clin Oncol; 1997 Jan; 15(1):292-6. PubMed ID: 8996155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
    Rossman J; Reddy V; Cantor A; Miley D; Robert F
    Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.
    Goto K; Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Matsumoto T; Ohmatsu H; Niho S; Kodama T; Shinkai T; Tamura T; Ohe Y; Kunitoh H; Yamamoto N; Nokihara H; Yoshida K; Sugiura T; Matsui K; Saijo N
    Br J Cancer; 2004 Aug; 91(4):659-65. PubMed ID: 15280919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.